- 3-[2-[4-(4-Fluorobenzoyl)piperidin-1-yl]ethyl]- 5,6,7,8-tetrahydro-4(3H)-quinazolinones: Serotonin 5-HT(2A) receptor antagonists endowed with potent central action
-
A series of 5,6,7,8-tetrahydro-4(3H)-quinazolinones substituted at the 3-position with 4-benzoyl-1-ethylpiperidine, 4-(4-fluorobenzoyl)-1-ethylpiperidine, 4-[bis-(4-fluorophenyl)methylene]-1-ethylpiperidine, or 4-(4-fluorophenyl)-1-propylpiperazine have been prepared and evaluated in binding assays to determine their affinity at serotonin 5-HT(2A) receptors as well as in a functional test, ie, wet dog shakes (WDS) induced by L-5-hydroxytryptophan (L-5-HTP), a behavioural response which is mediated by stimulation of 5-HT(2A) receptors. Among the compounds prepared, 3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-5,6,7,8-tetrahydro-4(3H) -quinazolinone (10a) and 2-methyl-3-[2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl]-5,6,7,8-tetrahydro -4(3H)-quinazolinone (10b) proved to be the most potent 5-HT(2A) receptor antagonists. In binding assays, the two compounds displayed similar affinity for 5-HT(2A) receptors in the nanomolar range to ketanserin and ritanserin. In the WDS test, they were even more potent than ketanserin and ritanserin. Compound 10b, which was found to possess the highest potency and duration of action in the WDS test, was chosen for a preliminary evaluation of its ability to inhibit ethanol intake in rats, a response linked to blockade of the central 5-HT(2A) receptors. This compound significantly reduced ethanol intake in rats from the first day of treatment. The results of the present study indicate that 10b is a potent centrally acting antagonist at 5-HT(2A), receptors.
- Claudi,Giorgioni,Scoccia,Ciccocioppo,Panocka,Massi
-
-
Read Online
- Convenient new synthesis of umeclidinium bromide
-
Umeclidinium bromide, a drug used for chronic obstructive pulmonary disease, is synthesized through a new intermediate of phenyl(quinuclidin-4-yl)methanone. This novel method with simple operation flow and cheap reagents, makes it suitable for scale up. The overall four-step process provides umeclidinium bromide in 29% yield and the purity up to 99.83%. The X-ray crystal structure of the drug molecule was first reported.
- Gu, Jianhui,Zhang, Jie,Wang, Xuan,Wang, Guoping
-
supporting information
p. 995 - 1000
(2018/05/23)
-